Gilead Sciences (NASDAQ:GILD) Price Target Raised to $135.00

Gilead Sciences (NASDAQ:GILD) had its target price lifted by Citigroup from $125.00 to $135.00 in a research report report published on Wednesday morning, MarketBeat Ratings reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

GILD has been the subject of a number of other research reports. UBS Group boosted their price target on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research note on Friday, August 8th. Daiwa America upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Rothschild & Co Redburn increased their price objective on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a research report on Friday, September 12th. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a report on Saturday, September 27th. Finally, Truist Financial raised Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $118.08.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $117.18 on Wednesday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The company has a 50 day simple moving average of $114.65 and a two-hundred day simple moving average of $110.25. Gilead Sciences has a fifty-two week low of $84.17 and a fifty-two week high of $121.83. The company has a market capitalization of $145.40 billion, a price-to-earnings ratio of 23.34, a P/E/G ratio of 0.79 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company’s revenue was up 1.4% on a year-over-year basis. During the same period last year, the company earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts expect that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 62.95%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $340,710.00. Following the completion of the sale, the insider directly owned 113,193 shares of the company’s stock, valued at $12,855,329.01. This trade represents a 2.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $283,925.00. Following the transaction, the chief financial officer directly owned 159,555 shares of the company’s stock, valued at $18,120,661.35. The trade was a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 82,000 shares of company stock valued at $9,402,130 over the last ninety days. 0.27% of the stock is currently owned by company insiders.

Institutional Trading of Gilead Sciences

Large investors have recently added to or reduced their stakes in the company. Smallwood Wealth Investment Management LLC bought a new position in shares of Gilead Sciences during the 1st quarter valued at approximately $25,000. GoalVest Advisory LLC raised its stake in Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares in the last quarter. Activest Wealth Management lifted its position in Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the last quarter. Harbor Asset Planning Inc. purchased a new position in shares of Gilead Sciences in the 2nd quarter worth $27,000. Finally, Goodman Advisory Group LLC bought a new stake in shares of Gilead Sciences in the 1st quarter worth about $29,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.